 Benitec Biopharma ASX: BLT, NASDAQ: BNTC Benitec or the Company, a biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference ddRNAi platform combining RNA interference with gene therapy, today announced its Appendix 4C for the quarter ending 31 December 2019. 